Allarity Therapeutics, Inc.
ALLRDrugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How ALLR's past catalysts played out
2X-121
Advanced Ovarian Cancer
PARP inhibitor 2X-121
Metastatic Breast Cancer
Irofulven
Metastatic Castration-Resistant Prostate Cancer Patients
LiPlaCis
Phase 1: Advanced or Refractory Solid Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
2X-121 | Phase 2 | Advanced Ovarian Cancer | - | - |
PARP inhibitor 2X-121 | Phase 2 | Metastatic Breast Cancer | - | - |
Irofulven | Phase 2 | Metastatic Castration-Resistant Prostate Cancer Patients | - | - |
LiPlaCis | Phase 2 | Phase 1: Advanced or Refractory Solid Tumours | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Allarity Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 4 drug candidates in Allarity Therapeutics, Inc.'s (ALLR) pipeline across Phase 2. Its lead program is 2X-121 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Allarity Therapeutics, Inc.'s next FDA catalyst?→
Allarity Therapeutics, Inc.'s (ALLR) next tracked catalyst is a Phase 2 expected March 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ALLR biotech catalysts?→
Add ALLR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Allarity Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.